Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 12/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710623 | 0.76 | MAOB (0.61) | — | |
| SCHEMBL6648775 | 0.72 | PARP1 (0.58) | PARP1 | |
| SCHEMBL12998216 | 0.71 | STS (0.57) | PARP1 | |
| SCHEMBL12998232 | 0.70 | STS (0.58) | PARP1 | |
| SCHEMBL12998231 | 0.70 | STS (0.58) | PARP1 | |
| SCHEMBL12998221 | 0.70 | STS (0.58) | PARP1 | |
| SCHEMBL30158836 | 0.70 | HSD17B10 (0.61) | PARP1 | |
| SCHEMBL25911476 | 0.70 | HSD17B10 (0.61) | PARP1 | |
| SCHEMBL12998214 | 0.69 | STS (0.57) | PARP1 | |
| SCHEMBL25153943 | 0.68 | KDM4E (0.48) | PARP1KCNH2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | DRD1 1469/4885PARP1 1/4885HRH3 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.